EUCTR2013-004158-81-Outside-EU/EEA进行中（未招募）1 期
A multi-centre, single-blind, parallel group, clinical evaluation of the efficacyand safety of clindamycin 1% / benzoyl peroxide 3% and azelaic acid 20% in thetopical treatment of mild to moderate acne vulgaris
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 220
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subjects who are males or females 12 to 45 years of age, inclusive.
- •2. Subjects with acne vulgaris who have:
- •- a minimum of 17 to a maximum of 60 inflammatory facial lesions (papules and
- •pustules), including the nose, and no more than 1 facial nodular cystic lesions.
- •- and a minimum of 20 to a maximum of 125 non-inflammatory facial lesions (open and closed comedones).
- •- and an ISGA score of 2 or 3.
- •3. Subjects agreeing not to use sun-beds or undergo any UV light treatment for 4 weeks prior to entering the study and to minimize the amount of exposure to direct sunlight for the duration of the study.
- •4. Subjects who are capable of understanding and willing to provide signed and dated written voluntary informed consent before any protocol-specific procedures are performed. Subjects under the legal age of consent must provide assent and have the written, informed consent of both parents or legal guardians.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 104
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 113
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Unable to comply with the requirement of the study.
- •2. Female patients who are pregnant, breast-feeding, or sexually active and not using reliable contraception and/or not prepared to do so for the duration of the trial (a negative pregnancy test must be confirmed at Visit 1, 3, 4 and 5, for all females if menarche has occurred).
- •3. Subjects who have any clinically relevant finding at their baseline physical examination or medical history such as severe systemic diseases or diseases of the facial skin other than acne vulgaris.
- •4. Subjects who have facial hair that may obscure the accurate assessment of acne grade.
- •5. Subjects who have a history or presence of regional enteritis or inflammatory bowel disease (eg, ulcerative colitis, pseudomembranous colitis, chronic diarrhea, or a history of antibiotic-associated colitis) or similar symptoms.
- •6. Prior Therapy: Have received treatment with the following therapies at the times specified prior to Baseline:
- •Systemic retinoids 6 months
- •systemic anitbiotics, investigational therapy, facial procedure (chemical or laser peel, microdermabrasion, artificial ultraviolet (UV) therapy, topical corticosteroids on the face or systemic corticosteroids - 4 weeks
- •Topical anitibiotics on the face, topical anti-acne medications (eg BPO, retinoids, azelaic acid, resorcinol, salicylates, sulfacetamide sodium and derivatives, glycolic acid - 2 weeks
- •Medications that are reported to exacerbate acne (eg. mega-doses of certain vitamins such as vitamin D, vitamin A an dvitamins B2, B6 and B12; haloperidol, halogens such as iodide and bromide; lithium, hydantoin; and phenobarbital) as these may impact efficacy assessments - 1 day
- •neuromuscular blocking agents (clindamycin has neuromuscular blocking activities, which may enhance the action of other neuromuscular blocking agents) - 1 day
- •drugs known to be photosensitizers (eg, thiazides, tetracyclines, fluoroquinolones, phenothiazines, sulfonamides) because of the possibility of increased phototoxicity - 1 day
- •7. Subjects who are unwilling to stop using the following types of facial products during the study: astringents, toners, abradants, facials, peels containing glycolic or other acids, masks, washes or soaps containing BPO, sulfacetamide sodium or salicylic acid, nonmild facial cleansers, or moisturizers that contain retinol, salicylic acid, or a- or ß- hydroxy acids.
- •8. Subjects who have a known hypersensitivity or previous allergic reaction to any of the active components (azaleic acid, lincomycin, clindamycin, BPO), or excipients of the study medication.
- •9. Use of estrogens, including oral, implanted, and topical contraceptives, androgens, or anti-androgenic agents of less than 12 consecutive weeks prior to start of study dosing (change of the dose or drug is not permitted between 12 weeks prior study dosing until end of the study).
研究者
相似试验
进行中（未招募）
不适用
A Multi-Centre, Single-Blind, Parallel Group, Clinical Evaluation of the Efficacy and Safety of Duac Gel (A Gel containing Clindamycin Phosphate [Equivalent to 1% Clindamycin] and 5% Benzoyl Peroxide) and Differin Gel (A Gel containing 0.1% Adapalene) in the Topical Treatment of Mild to Moderate Acne Vulgaris.Acne VulgarisClassification code 10000519EUCTR2004-002272-41-GBStiefel Laboratories International Division130
进行中（未招募）
1 期
A multi-center, double-blind, parallel-group, placebo-controlled, randomized study: evaluation of the efficacy and safety of brivaracetam in subjects (>= 16 to 70 years old) with Partial Onset Seizures.Estudio multicentrico, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos: evaluacion de la eficacia y la seguridad del brivaracetam en sujetos (edad >= 16 a 70 anos) con crisis de inicio parcial. - POS Phase 3Partial Onset SeizuresCrisis de inicio parcialMedDRA version: 9.1Level: LLTClassification code 10015037Term: EpilepsyEUCTR2006-006344-59-ESCB Pharma399
进行中（未招募）
不适用
A multi-center, double-blind, parallel-group, placebo-controlled, randomized study: evaluation of the efficacy and safety of brivaracetam in subjects (>= 16 to 70 years old) with Partial Onset Seizures. - POS Phase 3EUCTR2006-006344-59-NLCB Pharma500
进行中（未招募）
1 期
A multi-center, double-blind, parallel-group, placebo-controlled, randomized study: evaluation of the efficacy and safety of brivaracetam in subjects (>= 16 to 70 years old) with Partial Onset Seizures. - POS Phase 3Partial Onset SeizuresMedDRA version: 9.1Level: LLTClassification code 10015037Term: EpilepsyEUCTR2006-006344-59-FRCB Pharma399
进行中（未招募）
1 期
A multi-center, double-blind, parallel-group, placebo-controlled, randomized study: evaluation of the efficacy and safety of brivaracetam in subjects (>= 16 to 70 years old) with Partial Onset Seizures. - POS Phase 3Partial Onset SeizuresMedDRA version: 9.1 Level: LLT Classification code 10015037 Term: EpilepsyEUCTR2006-006344-59-GBCB Pharma399